Skip to main content

INVESTORS

Investors

Deal Headline:March 2023

Deal Headline:March 2023

Deal Headline:March 2023

Deal Headline:March 2023

Deal Headline:March 2023

$861M : CNS development Deal

$861M : CNS development Deal

$861M : CNS development Deal

$861M : CNS development Deal

$861M : CNS development Deal

BIORCHESTRA is proud to announce that we have signed an exclusive research and option agreement of up to $861M with a global biopharmaceutical company to leverage BIORCHESTRA’s Targeting Technology Platform (BDDS™) and develop nucleic acid therapies for the treatment of neurological disorders and against multiple targets.

WHAT’S NEW

News & Press releases

Filter

Press Release

BIORCHESTRA Wins Grand Prize in 2023 Merck Advance Biotech Grant Program

July 17, 2023
Recognition of outstanding in-vivo outcomes from a lead RNA program in CNS Underpinned by proprietary…
Press Release

BIORCHESTRA Announces Significant Progress in Studies of BMD-001 Drug Program

April 24, 2023
Encouraging non-human primate (NHP) findings support the progression of IV-formulated BMD-001 ahead of formal clinical studies for…
Press Release

BIORCHESTRA Expands Executive Leadership Team with the Appointment of David Oxley as Chief Business Officer

April 5, 2023
CAMBRIDGE, Mass. and DAEJEON, South Korea, April 5, 2023 — BIORCHESTRA, a biotherapeutics company focused on the treatment of rare and…